Clinical Trials
15 trialsNCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT03490838 2025-05-13
PROter
Advanced Accelerator Applications
Phase 1 Terminated
NCT04249947 2025-02-17
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Phase 1 Terminated
NCT03134027 2024-07-18
Immune PDX
Duke University
Terminated
NCT04221828 2022-03-29
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Phase 2 Terminated
NCT01094496 2020-02-13
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Celldex Therapeutics
Phase 2 Terminated
NCT02026960 2018-12-20
RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
Duke University
Phase NA Terminated
NCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT02386111 2018-07-26
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated
NCT01918605 2017-10-27
Protection of Rectum From High Radiation Doses Using a Spacer
University of Oulu
Phase NA Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT02483884 2017-03-22
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Lantheus Biosciences Ltd.
Phase 1/2 Terminated
NCT00147238 2012-08-07
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
M.D. Anderson Cancer Center
Phase NA Terminated